SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Walter Morton who wrote (2298)6/8/1999 1:45:00 PM
From: Rudy Saucillo  Read Replies (2) of 2742
 
<<So Rudy, are saying that if the buyer knows about the $31 Million agreement with PMC plus royalties and believes that the CIST intellectual property can help make that happen, then they would pay substantially more for CIST?>>

That's not quite what I was saying, Walter. Let me summarize:

(1) CIST is not worth $12-$18 per share as you implied. That's absolutely ludicrous.

(2) If Naismith finds a buyer for Cistron, I believe it will sell toward the lower end of John Metcalf's estimates...no less than 60 cents and probably no more than 75 cents/share. [Of course, that's still a double from the current price.]

(3) There's no reason to believe Cistron will ever see anything close to the $31MM from PMC (IMO).

Hope that clears things up!
Rudy
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext